Immune hydrops fetalis
diseaseOn this page
Also known as IHFimmune fetal edemaimmune fetal hydropsimmune foetal hydropsimmune foetal oedemaimmune HF
Summary
Immune hydrops fetalis (MONDO:0018221) is a disease. A subtype of hydrops fetalis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (United Kingdom) [Orphanet-validated]
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Prevalence at birth | 1-5 / 10 000 | 33.3 | United Kingdom | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | immune hydrops fetalis |
| Mondo ID | MONDO:0018221 |
| Orphanet | 364013 |
| ICD-11 | 1589938690 |
| NCIT | C111904 |
| SNOMED CT | 15539009 |
| UMLS | C0455990 |
| MedGen | 105328 |
| GARD | 0021561 |
| Is cancer (heuristic) | no |
Also known as: IHF · immune fetal edema · immune fetal hydrops · immune foetal hydrops · immune foetal oedema · immune HF
Disease family
This is a subtype of hydrops fetalis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › disorder of development or morphogenesis › developmental defect during embryogenesis › hydrops fetalis › immune hydrops fetalis
Related subtypes (1): non-immune hydrops fetalis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.